We are live on !
Find out more
Kinnevik Portfolio holdings
AUM
$65.6M
Turnover
0%
1-Year Est. Return
25.95%
This Fund
S&P 500
This Quarter Est. Return
+11.99%
1 Year Est. Return
-25.95%
3 Year Est. Return
-51.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$77.7M
AUM Growth
+$3.18M
(+4.3%)
Cap. Flow
-$4.24M
Cap. Flow % of AUM
Cap. Flow %
-5.46%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
2
New
–
Increased
1
Reduced
–
Closed
1
Avg Time Held
0.5
years
Top 10 Avg Time Held
0.5
years
Top 20 Avg Time Held
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Recursion Pharmaceuticals
RXRX
|
+$19.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BBLN
Babylon Holdings
BBLN
|
+$23.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
KAM
EVP
A
Kinnevik's Q2 2023 Portfolio in Review
As of Q2 2023, Kinnevik held 2 positions worth $77.7M, up 4.3% from $74.5M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Kinnevik withdrew a net $4.24M in Q2 2023, closing 1 position. Its most notable exit was Babylon Holdings, an estimated $23.5M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Kinnevik added an estimated $19.3M to Recursion Pharmaceuticals.
- Kinnevik added most to Recursion Pharmaceuticals in Q2 2023, an estimated $19.3M increase.
- Kinnevik fully exited Babylon Holdings in Q2 2023, selling an estimated $23.5M.
- Kinnevik's ten largest holdings make up 100% of its $77.7M portfolio in Q2 2023.
- Kinnevik opened 0 new positions and closed 1 in Q2 2023.
- Kinnevik's portfolio value rose 4.3% quarter-over-quarter to $77.7M.
Based on Kinnevik's 13F filing for Q2 2023, filed 25 Jul 2023.